Richard Jameson assumes position as Camurus’ Chief Commercial Officer

Lund — 20 June 2016 — Further to the announcement on December 14, 2015, Camurus
(NASDAQ STO: CAMX) today announces that Richard Jameson has assumed the position
of Chief Commercial Officer and member of the Executive Management Team.

Richard Jameson has broad experience from different commercial roles including
sales leadership, marketing, market access and general management across a
number of specialty pharmaceutical companies, including, Serono, Schering Plough
and Ferring. In 2010 he joined Indivior (then Reckitt Benckiser Pharmaceuticals)
as General Manager for Northern Europe (UK and Nordics) and led the building of
the regional commercial team after the buyback of the buprenorphine franchise
from Schering Plough. For the last three years he has been serving as Area
Director EMEA at Indivior and was responsible for the leadership of a commercial
organization across Europe, the Middle-East and Africa, focusing on the
buprenorphine franchise (Subutex® and Suboxone®) and the treatment of opioid
dependence. He was also a part of the leadership group for the demerger of
Indivior from Reckitt Benckiser PLC in 2014.

“Richard brings a wealth of experience in commercial strategy, marketing and
general management to Camurus at a time when we are expanding our business and
starting the build-up of our commercial organization in Europe” said Fredrik
Tiberg, President and CEO, Camurus.” His knowledge of the evolving European
markets and previous commercialization successes within addiction and other
specialty indication areas will serve us well as we prepare for the anticipated
approval and launch of our long-acting buprenorphine products for treatment of
opioid dependence."

“I am delighted to join the successful team at Camurus at this exciting stage of
the company’s development” said Richard Jameson, Chief Commercial Officer “I
look forward to initiating the commercialization of our innovative specialty
medicines. The initial focus will be on ensuring that opioid dependent patients
in Europe will have access to our weekly and monthly buprenorphine products,
CAM2038, currently being assessed in a global Phase 3 program. The products
represent the first innovation in this field for more than a decade, with the
potential to transform the treatment of patients with opioid dependence.”

About Camurus
Camurus is a Swedish research-based pharmaceutical company committed to
developing and commercialising innovative and differentiated medicines for the
treatment of severe and chronic conditions. New drug products with best-in-class
potential are conceived based on the proprietary FluidCrystal® drug delivery
technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes
products for treatment of cancer, endocrine diseases, pain and addiction,
developed in-house and in collaboration with international pharmaceutical
companies. The company’s shares are listed on Nasdaq Stockholm under the ticker
“CAMX”. For more information, visit www.camurus.com.

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92
ir@camurus.com

The information was submitted for publication at 8.00 a.m. on 20 June 2016.